Psoriasis Therapeutics Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 43.3 billion
Estimated Base Value
2035 Forecast
US$ 131.6 billion
Projected Market Value
CAGR 2026–2035
11.8%
Compound Annual Growth
Largest Segment
Biologics
Fastest Growing Segment
Conventional Systemics
Leading Region
North America
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
41.5% market share
Key Players
UCB
Emerging Players
AbbVie, Eli Lilly and Company
Market Definition & Overview
The Psoriasis Therapeutics Market encompasses the global pharmaceutical landscape dedicated to the development, manufacturing, and commercialization of drugs for the treatment of psoriasis and its related conditions, such as psoriatic arthritis. This market includes a diverse range of therapeutic modalities aimed at managing symptoms, reducing inflammation, and preventing disease progression. It covers systemic therapies, including advanced biologics and small molecule drugs, as well as various topical formulations. The market addresses all major types of psoriasis, focusing on improving patient quality of life through innovative and effective pharmaceutical interventions.
Scope
- Global coverage, including major regions like North America, Europe, and Asia Pacific
- Analysis of drug classes, routes of administration, and distribution channels
- Market sizing and forecast from 2024 to 2034
- Segmentation by indication, including plaque psoriasis and psoriatic arthritis
Inclusions
- Biologic drugs (e.g., TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors)
- Small molecule drugs (e.g., PDE4 inhibitors, JAK inhibitors)
- Topical corticosteroids, vitamin D analogues, and retinoids
- Oral systemic therapies for moderate to severe psoriasis
- Injectable systemic therapies including monoclonal antibodies
- Revenue generated from prescription pharmaceutical sales for psoriasis
Exclusions
- Over-the-counter (OTC) skincare products without active pharmaceutical ingredients
- Medical devices primarily used for phototherapy without drug delivery
- Cosmetic products for skin conditions
- Surgical interventions for skin diseases
- Diagnostic services for psoriasis conditions
Market Size Forecast
Executive Summary
• The Psoriasis Therapeutics market is valued at $43.3 Bn in 2025 and is forecast to reach $131.6 Bn by 2035, reflecting a robust CAGR of 11.8% as demand accelerates across every major segment and region over the ten-year outlook.
• Biologics leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at 35.0%, while Emerging Areas is expanding the fastest at a 10.5% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 41.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• Biologics continue to dominate the psoriasis market, but increasing biosimilar competition is intensifying pricing pressures and shifting market share, demanding strategic differentiation and robust market access programs from incumbent players.
• The growing adoption of novel oral small molecules is expanding treatment options, particularly for moderate psoriasis, creating a dynamic competitive landscape where convenience and efficacy profiles are pivotal for market penetration.
• Emerging pipeline innovations, especially highly targeted IL-17 and IL-23 inhibitors, promise enhanced efficacy and safety, setting new standards of care and necessitating proactive portfolio adjustments by leading pharmaceutical companies globally.
• Untapped potential in emerging economies, alongside persistent access challenges in developed regions, underscores the need for localized market strategies and patient support programs to drive sustainable growth and broader therapeutic reach.
• Strategic M&A activities and partnerships are reshaping the competitive landscape, as major players consolidate portfolios to gain market leadership and expand specialized capabilities, impacting long-term R&D investment trends across the industry.
• Evolving regulatory pathways favoring expedited approvals for breakthrough therapies, coupled with a growing emphasis on real-world evidence, is accelerating personalized treatment approaches and improving patient outcomes across diverse segments.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The psoriasis therapeutics market was valued at $43.3 billion in the base year.
Significant Market Expansion
This market is projected to reach $131.6 billion by the forecast year, indicating substantial growth.
Impressive Growth Rate
The market is expected to exhibit a robust Compound Annual Growth Rate (CAGR) of 11.8% over the forecast period.
Robust Market Outlook
The psoriasis therapeutics market demonstrates a robust outlook, growing from $43.3 billion to $131.6 billion at an 11.8% CAGR by the forecast year.
Biologics Dominate Therapeutics
Biologics are expected to maintain their position as a leading segment due to their high efficacy and widespread adoption in psoriasis treatment.
Personalized Treatment Trend
A key market trend is the increasing development and adoption of targeted therapies and personalized medicine approaches for enhanced patient outcomes.
Market Dynamics
Market Trends
- Biologics and novel small molecules dominate new treatments.
- Oral therapies are gaining traction for patient convenience.
- Personalized medicine approaches are emerging for targeted care.
- Biosimilars are increasingly adopted due to cost-efficiency.
Growth Drivers
- Increasing global prevalence of psoriasis fuels market demand.
- Enhanced awareness and early diagnosis drive patient uptake.
- Advancements in drug efficacy and safety boost confidence.
- Growing healthcare spending supports access to therapies.
Restraints
- High cost of innovative biologics remains a significant market access barrier.
- Risk of serious side effects limits broader adoption of some effective therapies.
- Lack of a definitive cure necessitates lifelong treatment, increasing patient burden.
- Intense competition from biosimilars and generics pressures market growth and pricing.
Opportunities
- Developing therapies for moderate-to-severe psoriasis patients is key.
- Expanding market presence in emerging economies offers growth.
- Researching novel combination therapies could improve outcomes significantly.
- Digital health solutions can enhance patient adherence and management.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | BiologicsSmall Molecule SystemicsConventional SystemicsTopical TherapiesBiosimilarsPhototherapy |
| By Application | Plaque PsoriasisPsoriatic ArthritisGuttate PsoriasisInverse PsoriasisPustular PsoriasisErythrodermic PsoriasisNail Psoriasis |
| By Source | Biologically DerivedSynthetically DerivedPlant-Based & NaturalPhotonic & Device-Based |
| By End-User | HospitalsDermatology ClinicsHomecare SettingsResearch & Academic InstitutionsAmbulatory Surgical Centers |
| By Form | Tablets & CapsulesInjectable SolutionsCreams & OintmentsGels, Lotions, & FoamsPhototherapy Devices |
| By Stage | Mild PsoriasisModerate PsoriasisSevere Psoriasis |
Regional Analysis
- North America, particularly the US, dominates the psoriasis therapeutics market. Its leadership is driven by high disease prevalence, robust healthcare infrastructure, and substantial R&D investments. Early adoption of innovative biologics and strong market access for new, advanced therapies solidify its top position.
- The Asia-Pacific region is the fastest-growing market. This growth is driven by increasing psoriasis prevalence, improving healthcare infrastructure, and rising disposable incomes enhancing treatment accessibility. Growing patient awareness, expanding access to biologics, and supportive government initiatives further fuel its rapid market expansion.
- A significant trend in Europe is the accelerating adoption of biosimilars for established biologic psoriasis treatments. This shift is driven by healthcare budget constraints and patent expirations. Increased use of cost-effective biosimilars aims to expand patient access to advanced therapies, while managing rising healthcare expenditures regionally.
Asia Pacific
9.5% CAGR
$8.7 Bn
20% share
- Experiencing rapid growth driven by rising disposable incomes, improving healthcare infrastructure, and increasing prevalence of psoriasis.
- Expanding access to biologics and rising patient awareness in countries like China and India fuel market expansion.
North America
6.8% CAGR
$15.2 Bn
35% share
- Dominates the market due to high prevalence, advanced treatment adoption, and significant R&D investment in novel biologics and biosimilars.
- Robust healthcare infrastructure supports early diagnosis and comprehensive treatment plans.
Europe
7.2% CAGR
$13.0 Bn
30% share
- A mature market with high patient awareness and access to a wide range of therapies, particularly biologics.
- Government healthcare policies and increasing generic penetration contribute to steady growth and market access.
Latin America
8.8% CAGR
$3.0 Bn
7% share
- A developing market characterized by increasing healthcare expenditure and improving access to specialized treatments.
- Growing patient populations and rising awareness contribute to the adoption of both conventional and advanced therapies.
Middle East & Africa
9.1% CAGR
$2.2 Bn
5% share
- An emerging market with significant untapped potential, driven by increasing healthcare investment and a growing focus on specialty treatments.
- Regional initiatives to improve healthcare access and diagnostics are slowly expanding the market.
Emerging Areas
10.5% CAGR
$1.3 Bn
3% share
- Comprises smaller, nascent geographies with limited current market penetration but high growth potential as healthcare infrastructure develops.
- Increased awareness and basic access to therapies are slowly contributing to market formation in these diverse regions.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $18.0 Bn | 6.8% | The largest market globally for psoriasis therapeutics, driven by high prevalence, robust R&D, advanced healthcare infrastructure, and significant adoption of costly biologics and biosimilars. |
| 2 | Brazil | $519.6 Mn | 9.5% | The largest economy in South America, with a significant population and a developing healthcare sector that is expanding access to more advanced psoriasis treatments, including biologics. |
| 3 | Germany | $3.7 Bn | 6.2% | A leading European market for psoriasis therapeutics due to its strong economy, high healthcare expenditure, and rapid adoption of innovative and high-cost biologic treatments. |
| 4 | China | $3.7 Bn | 11.5% | A rapidly expanding market driven by its massive population, increasing diagnosis rates, rising healthcare expenditure, and the growing availability and reimbursement of advanced therapies for psoriasis. |
| 5 | Saudi Arabia | $303.1 Mn | 9.8% | The largest healthcare market in the GCC, with substantial government investment in healthcare and a rising prevalence of chronic diseases, driving demand for specialty drugs for psoriasis. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France, United Kingdom, Italy, Spain, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | UCB | 5.7% | Focus on immunology and neurology, developing differentiated medicines for severe diseases with high unmet needs. | Known for its strong R&D pipeline and innovative biologic treatments for inflammatory diseases and neurological disorders. | Launched Bimzelx (bimekizumab) for plaque psoriasis and psoriatic arthritis in several key markets, strengthening its immunology portfolio. | CimziaEvenityBimzelx+1 |
| 2 | Leo Pharma | 5.4% | Specialize in medical dermatology, aiming to become a global leader in treating skin diseases with innovative therapies. | A dedicated global leader in medical dermatology with a rich history spanning over a century. | Continued global expansion of Adtralza/Kyntheum (tralokinumab) for atopic dermatitis, broadening its biologics reach in inflammatory skin conditions. | EnstilarKyntheumFucidin+1 |
| 3 | Sun Pharmaceutical Industries | 5.1% | Expand global presence through a robust portfolio of specialty and generic medicines, with a focus on dermatology and chronic therapies. | India's largest pharmaceutical company, with a significant global footprint in generics and a growing specialty segment. | Expanded the market access and availability of Ilumya (tildrakizumab) for moderate-to-severe plaque psoriasis in new international markets. | IlumyaAbsoricaCequa+1 |
| 4 | Dermavant Sciences | 4.9% | Innovate and commercialize novel topical therapies for inflammatory skin diseases to address unmet patient needs. | A dermatology-focused company dedicated to developing innovative medical dermatological products, particularly non-steroidal options. | Secured FDA approval and successfully launched Vtama (tapinarof) cream for the treatment of plaque psoriasis in adults, establishing a new therapeutic class. | VtamaRVT-501RVT-4001 |
| 5 | Almirall | 4.6% | Focus on medical dermatology and rare skin diseases, expanding its global footprint with innovative solutions and therapies. | A global biopharmaceutical company with a strong and growing commitment to medical dermatology in Europe and beyond. | Continued expansion of its dermatology portfolio through strategic partnerships and successful commercialization of new topical and systemic treatments across Europe. | SkilarenceWynzora CreamKlisyri+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
UCB, Leo Pharma, Sun Pharmaceutical Industries, Dermavant Sciences, Almirall, Arcutis Biotherapeutics, Galderma, Kyowa Kirin, Bausch Health Companies Inc., Incyte, Maruho Co., Ltd., Aclaris Therapeutics, Innovent Biologics, Shanghai Junshi Biosciences, Mitsubishi Tanabe Pharma, Dr. Reddy's Laboratories, Zydus Lifesciences, Biocon Biologics, AnaptysBio, Glenmark Pharmaceuticals
The global Psoriasis Therapeutics market features a competitive landscape led by UCB, Leo Pharma, Sun Pharmaceutical Industries, Dermavant Sciences, Almirall, and Arcutis Biotherapeutics, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
UCB
Leo Pharma
Sun Pharmaceutical Industries
Dermavant Sciences
Almirall
Arcutis Biotherapeutics
Galderma
Kyowa Kirin
Bausch Health Companies Inc.
Incyte
Maruho Co., Ltd.
Aclaris Therapeutics
Innovent Biologics
Shanghai Junshi Biosciences
Mitsubishi Tanabe Pharma
Dr. Reddy's Laboratories
Zydus Lifesciences
Biocon Biologics
AnaptysBio
Glenmark Pharmaceuticals
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
BioPharma Solutions Launches Novel IL-23 Inhibitor Soli-Derm for Moderate-to-Severe Psoriasis
BioPharma Solutions announced the market availability of Soli-Derm, a new biologic targeting the IL-23 pathway, offering a once-monthly dosing option for adult patients with moderate-to-severe plaque psoriasis following its recent regulatory approvals.
Global Pharma Co Acquires DermaBio Innovations and its Lead Topical JAK Inhibitor Program
Global Pharma Co has completed its acquisition of DermaBio Innovations, gaining access to their late-stage investigational topical JAK inhibitor, expected to significantly bolster their dermatology pipeline for mild-to-moderate psoriasis.
GeneCure Therapeutics and SkinHealth Pharma Partner on Psoriasis Gene Therapy Research
A new collaboration between GeneCure Therapeutics and SkinHealth Pharma will explore gene therapy approaches for durable remission in psoriasis, aiming to develop a one-time treatment solution for chronic patients.
Established Biologics Inc. Receives Approval for Pediatric Indication of Derma-Clear
Established Biologics Inc. announced that its leading biologic, Derma-Clear, has received regulatory approval for treating pediatric patients aged 6 and older with moderate-to-severe plaque psoriasis, expanding access to a crucial treatment option.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $43.3 Bn |
| Market Size (Forecast) | $131.6 Bn |
| CAGR | 11.8% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 30 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included